Clinical Trial

VEL-101 to Prevent Rejection After Kidney Transplantation

Name: VEL-101 to Prevent Rejection After Kidney Transplantation — clinical trial record (NCT07290777)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: RENGEVITY-201

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This study will evaluate the safety and efficacy of VEL-101 compared with tacrolimus in patients undergoing kidney transplantation.

Trial Details

NCT Number	NCT07290777
Lead Sponsor	Veloxis Pharmaceuticals
Conditions	Transplantation, Kidney
Enrollment	120 participants
Start Date	2026-07
Primary Completion	2028-10 (estimated)
Study Completion	2028-10 (estimated)
Updated on ClinicalTrials.gov	2025-12-18